您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Teriflunomide
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Teriflunomide
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Teriflunomide图片
CAS NO:108605-62-5
规格:≥98%
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议
1g电议
2g电议
5g电议
10g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)270.21
FormulaC12H9F3N2O2
CAS No.108605-62-5
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 32 mg/mL (118.4 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Other info
Chemical Name: (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide.
InChi Key: UTNUDOFZCWSZMS-YFHOEESVSA-N
InChi Code: InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-
SMILES Code: C/C(O)=C(C#N)/C(NC1=CC=C(C(F)(F)F)C=C1)=O
SynonymsA77 1726, HMR-1726; A77 1726; Aubagio; A771726; A-771726; HMR1726; HMR 1726; teriflunomide; trade name: Aubagio.
实验参考方法
In Vitro

In vitro activity: Teriflunomide primarily acts as an inhibitor of dihydroorotate dehydrogenase (DHODH), a key mitochondrial enzyme involved in the de novo synthesis of pyrimidines in rapidly proliferating cells. By reducing the activity of high-avidity proliferating T lymphocytes and B lymphocytes, teriflunomide likely attenuates the inflammatory response to autoantigens in MS. Thus, teriflunomide can be considered a cytostatic rather than a cytotoxic drug to leukocytes.

In VivoTeriflunomide has demonstrated beneficial effects in two independent animal models of demyelinating disease. In the dark agouti rat model of experimental autoimmune encephalitis (EAE), teriflunomide administration results in clinical, histopathological, and electrophysiological evidence of efficacy both as a prophylactic and therapeutic agent. Similarly, in the female Lewis rat model of EAE, teriflunomide administration results in beneficial prophylactic and therapeutic clinical effects, with a delay in disease onset and symptom severity.
Animal model Rats
Formulation & Dosage N/A
ReferencesTher Clin Risk Manag. 2013;9:177-90.